Everus Construction Group, Inc.
ECG
$168.32
+11.52%
Everus Construction Group, Inc. is a construction solutions provider offering specialty contracting services across the U.S., primarily through its Electrical & Mechanical (E&M) and Transmission & Distribution (T&D) segments. The company operates as a significant player in the engineering and construction industry, focusing on critical infrastructure like electrical wiring, fire suppression systems, and utility networks. The current investor narrative is dominated by its explosive post-IPO performance and strong revenue growth, with recent attention likely fueled by its Q4 2025 earnings report showing a 33% year-over-year revenue increase, positioning it as a high-growth story within the industrials sector.…
ECG
Everus Construction Group, Inc.
$168.32
ECG 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Everus Construction Group, Inc.'s 12-month outlook, with a consensus price target around $218.82 and implied upside of +30.0% versus the current price.
Average Target
$218.82
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$135 - $219
Analyst target range
Analyst coverage for ECG appears limited, with only one analyst providing estimates for EPS and revenue, and a handful of firms issuing ratings. The institutional ratings show a generally bullish sentiment among those who cover it, with recent actions from Stifel and Freedom Broker maintaining 'Buy' ratings, while DA Davidson has a 'Neutral' stance. The consensus recommendation among active ratings leans bullish, but the very low number of analysts signals this is a stock with limited institutional research coverage. The single analyst's estimates provide a target range, with an average EPS estimate of $5.73 for the coming period, bracketed by a low of $5.71 and a high of $5.76. The extremely tight range between the low and high EPS estimates indicates very high conviction in the near-term earnings forecast from that analyst. However, the lack of a broad consensus price target and the minimal number of covering analysts typically implies higher volatility and less efficient price discovery, as the stock's valuation is not being scrutinized by a deep bench of research professionals. This environment can lead to larger price swings on company-specific news.
Bulls vs Bears: ECG Investment Factors
The evidence currently favors the bull case, driven by explosive revenue growth (33% YoY), pristine financial health (D/E 0.17), and powerful technical momentum (229% 1-year gain). However, the bear case presents significant near-term risks, primarily centered on valuation. The single most important tension in the investment debate is whether ECG's accelerating revenue growth can sustainably justify its valuation, which has expanded to a historical peak (P/E 21.6x vs. 12.9x in Q1 2025). If growth decelerates or margins compress further, the stock's elevated multiple could contract sharply. Conversely, if the company continues to deliver 30%+ growth while maintaining or improving profitability, the current valuation could be seen as reasonable, supporting further upside.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue grew 33.2% YoY to $1.01B, accelerating from $826.6M in Q1 2025. This multi-quarter sequential growth solidifies ECG as a high-growth story within the industrials sector, driven by strong demand in its Electrical & Mechanical segment.
- Strong Financial Health & Low Leverage: The balance sheet is robust with a debt-to-equity ratio of 0.17 and a current ratio of 1.76, indicating minimal solvency risk and ample liquidity. The company generated $90.0M in TTM free cash flow, providing internal funding for continued expansion.
- High Return on Equity: Return on Equity stands at 32.0%, demonstrating highly effective use of shareholder capital. This metric, combined with a trailing P/E of 21.6x, suggests the market is rewarding efficient growth, though the forward P/E of 27.3x implies high expectations.
- Powerful Technical Momentum: The stock is up 229.3% over the past year and 52.7% over the past three months, showing accelerating momentum. It trades at 95% of its 52-week high ($137.64), confirming a sustained uptrend driven by company-specific catalysts, not just market beta.
Bearish
- Valuation at Historical Peak: The trailing P/E of 21.6x is near the top of its own historical range, up from 12.9x at the end of Q1 2025. Trading at these elevated multiples leaves little room for error and increases sensitivity to any earnings disappointment or growth deceleration.
- Signs of Margin Compression: Despite 33% revenue growth, Q4 2025 net margin declined to 5.4% from 5.8% in Q3, and gross margin was 11.6%. This indicates potential cost pressures or competitive intensity that could erode profitability even as the top line expands.
- Limited Analyst Coverage & Scrutiny: Only one analyst provides EPS estimates, and institutional ratings are sparse. This low coverage typically leads to higher volatility and less efficient price discovery, as the stock's valuation is not being stress-tested by a broad research bench.
- High Volatility & Technical Overextension: The stock has experienced a max drawdown of -20.26% during its run-up and trades just 5% below its 52-week high after a 229% yearly gain. This suggests the rally may be overextended, increasing the risk of a sharp correction on any negative news.
ECG Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 229.3% gain over the past year. With a current price of $130.34, it is trading at approximately 95% of its 52-week high of $137.64, indicating it is near the peak of its recent range and reflecting strong bullish momentum, though also suggesting potential for overextension. The 1-month and 3-month price changes of +12.6% and +52.7%, respectively, show that short-term momentum is not only positive but accelerating significantly compared to the longer-term trend, confirming the strength of the uptrend without any concerning divergence. Recent momentum is exceptionally strong, with the stock up 12.6% over the past month and 52.7% over the past three months, far outpacing the S&P 500's returns of 0.4% and -2.0% over the same periods. This massive relative strength, quantified at 12.2 and 54.8 points respectively, underscores intense buying pressure and suggests the rally is being driven by company-specific catalysts rather than broad market moves. The price action shows a decisive breakout from a consolidation range in late February, with the stock gapping from around $104 to over $130. Key technical support is anchored at the 52-week low of $34.36, though a more relevant near-term support level is likely around the $110-$115 area where the stock consolidated in March. Immediate resistance is at the 52-week high of $137.64; a breakout above this level would signal a continuation of the powerful uptrend. The stock exhibits high volatility, with a beta implied by its massive outperformance versus the market, meaning position sizing is critical as swings can be significantly larger than the overall market.
Beta
—
—
Max Drawdown
-20.3%
Largest decline past year
52-Week Range
$44-$170
Price range past year
Annual Return
+270.7%
Cumulative gain past year
| Period | ECG Return | S&P 500 |
|---|---|---|
| 1m | +35.9% | +10.4% |
| 3m | +96.4% | +5.5% |
| 6m | +71.2% | +8.0% |
| 1y | +270.7% | +28.4% |
| ytd | +88.7% | +6.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ECG Fundamental Analysis
Revenue growth is robust and accelerating, with Q4 2025 revenue reaching $1.01 billion, representing a 33.2% year-over-year increase. This growth is part of a clear multi-quarter acceleration, as quarterly revenue has climbed sequentially from $826.6 million in Q1 to over $1 billion in Q4. The Electrical & Mechanical segment, which generated $408 million in the latest period (data not available for T&D segment in same period), is the primary growth driver, benefiting from strong demand in both public and private sector construction. This trajectory solidifies ECG as a high-growth story within its sector. The company is profitable, with Q4 2025 net income of $55.3 million and a net margin of 5.4%. Gross margin for the quarter was 11.6%, which is relatively thin but consistent for the capital-intensive construction industry. However, profitability metrics show some fluctuation; the net margin of 5.4% in Q4 is down from 5.8% in Q3, indicating potential margin compression despite top-line growth. The full-year picture from key metrics shows a net margin of 5.4% and an operating margin of 7.1%, suggesting the company converts revenue to operating profit efficiently for its industry. The balance sheet is healthy with a strong current ratio of 1.76 and a very low debt-to-equity ratio of 0.17, indicating minimal financial leverage and low solvency risk. The company generated $90.0 million in trailing twelve-month free cash flow, providing internal funding for growth. Return on Equity is strong at 32.0%, demonstrating effective use of shareholder capital. The combination of strong cash generation, low debt, and high ROE paints a picture of a financially sound company with ample capacity to invest in further expansion.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+0.33%
YoY Comparison
Gross Margin
+0.11%
Latest Quarter
Free Cash Flow
$90009000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ECG Overvalued?
Given a positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 21.6x, while the forward P/E is 27.3x based on estimated EPS. The higher forward multiple suggests the market is pricing in expectations for earnings growth, though the gap also implies that near-term earnings may see some compression relative to the current stock price surge. Compared to industry averages, ECG's valuation presents a mixed picture. Its trailing P/E of 21.6x is difficult to contextualize without a specific sector average, but its Price/Sales ratio of 1.17x and EV/Sales of 1.81x are likely reasonable for a high-growth industrial company. The PEG ratio of 0.54, based on trailing metrics, suggests the stock is undervalued relative to its growth rate if that growth is sustainable, as a PEG below 1.0 typically indicates a potentially attractive valuation. Historically, the stock's own valuation has expanded dramatically with its price surge. The current trailing P/E of 21.6x is significantly higher than its P/E of 12.9x at the end of Q1 2025 and 19.8x at the end of Q4 2025. This places the stock near the top of its own historical valuation range since its IPO, indicating the market is pricing in highly optimistic expectations for future growth and profitability. Trading at these elevated historical multiples leaves little room for error and increases sensitivity to any earnings disappointment.
PE
21.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 13x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: ECG's primary financial risk is margin compression amidst rapid growth. The Q4 2025 net margin of 5.4% declined from 5.8% in Q3, and the gross margin of 11.6% is thin, even for the construction industry. While revenue grew 33% YoY, this margin pressure indicates that costs are rising, potentially eroding the bottom-line benefits of top-line expansion. The company's valuation (forward P/E 27.3x) is heavily dependent on continued high growth and margin stability; any miss on these fronts could trigger a significant de-rating.
Market & Competitive Risks: The stock trades at a premium valuation relative to its own history, with a trailing P/E of 21.6x, up from 12.9x less than a year ago. This creates substantial valuation compression risk if sector multiples contract or if ECG's growth narrative falters. The stock exhibits high volatility, implied by its massive 229% yearly gain and 54.8 points of 3-month relative strength versus the S&P 500, making it sensitive to broader market rotations away from high-momentum, high-growth names. Limited analyst coverage (only one providing estimates) exacerbates this volatility, as price discovery is less efficient.
Worst-Case Scenario: The worst-case scenario involves a simultaneous deceleration in revenue growth and further margin compression, triggered by increased competition or a slowdown in infrastructure spending. This would break the high-growth narrative supporting the elevated P/E multiple. Analysts, though few, would likely downgrade estimates, and momentum investors could exit en masse. A realistic downside could see the stock re-test its recent consolidation support around $110 (a -15% drop) or, in a severe de-rating towards its historical average P/E, fall towards the $80-$90 range. From the current price of $130.34, this implies a potential loss of 15-35%, with the 52-week low of $34.36 representing an extreme -74% downside in a catastrophic failure of the business model, though that level is unlikely barring a fundamental collapse.